Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting
Vanda Pharmaceuticals has reported positive results from the Phase III clinical trial, Study 3601, assessing its Nereus oral therapy to prevent vomiting triggered by GLP-1 receptor agonist treatments.
The post Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting appeared first on Clinical Trials Arena .